View Future GrowthKaken Pharmaceutical 過去の業績過去 基準チェック /06Kaken Pharmaceuticalの収益は年間平均-12.2%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間9.7% 3.2%割合で 増加しています。主要情報-12.22%収益成長率-11.89%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率3.16%株主資本利益率-2.63%ネット・マージン-5.06%次回の業績アップデート13 May 2026最近の業績更新お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025お知らせ • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025すべての更新を表示Recent updatesお知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026お知らせ • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • May 12+ 3 more updatesKaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.お知らせ • Apr 11Kaken Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecast for Fiscal Year Ended March 31, 2025Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025.お知らせ • Mar 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the purchase agreement and stock purchase. Completion of the stock purchase is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the stock purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor and Leerink Partners LLC acted as Financial advisor to Aadi Bioscience, Inc. Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million on March 25, 2025.お知らせ • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025お知らせ • Feb 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 1,800,000 shares, representing 4.53% for ¥9,000 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock.お知らせ • Dec 22Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. Completion of the Stock Purchase is subject to customary closing conditions, including the approval of the Purchase Agreement and the Stock Purchase by the holders of a majority of the outstanding shares of Aadi’s capital stock entitled to vote to approve the Purchase Agreement and Stock Purchase, all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the Stock Purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor toお知らせ • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025お知らせ • Sep 03Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024お知らせ • Jun 26Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024お知らせ • May 16Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.お知らせ • Mar 03Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q4, 2024 results on May 09, 2024お知らせ • Dec 08Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 06, 2024お知らせ • Nov 15+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥176.92.お知らせ • Sep 19Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)お知らせ • Aug 30Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 08, 2023お知らせ • Aug 18+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided dividend forecast for second quarter of 2024 and fiscal year ending March 31, 2024. For the quarter, the company expects to pay a dividend of ¥75 against ¥75 paid last year.For the year, the company expects to pay a dividend of ¥75 against ¥75 paid last year.お知らせ • May 28Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023お知らせ • May 12Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.お知らせ • Dec 28Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 03, 2023収支内訳Kaken Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:KKPC.F 収益、費用、利益 ( )JPY Millions日付収益収益G+A経費研究開発費31 Dec 2575,662-3,83219,91923,81330 Sep 2582,01965119,65624,42430 Jun 2594,64812,46218,67321,10931 Mar 2594,03513,94518,50118,72531 Dec 2493,34920,52516,89214,59830 Sep 2487,24518,24316,24612,77830 Jun 2472,1487,26916,30612,94131 Mar 2472,0448,02516,16512,54331 Dec 2372,0962,96616,10217,98130 Sep 2372,3363,54416,09717,19730 Jun 2372,9375,04315,68516,35931 Mar 2372,9845,44015,47615,78931 Dec 2273,8998,45215,5978,69530 Sep 2275,2658,79215,7268,74230 Jun 2275,7789,09415,7978,58531 Mar 2276,0349,54915,8338,42031 Dec 2175,60512,71716,2587,90930 Sep 2175,77812,90016,2707,47730 Jun 2175,36212,94716,3617,02831 Mar 2174,97913,40516,1556,73631 Dec 2076,13614,75016,1596,53930 Sep 2080,85117,04916,3476,35130 Jun 2084,96718,36416,5906,38231 Mar 2089,23219,37017,3206,41831 Dec 1991,75919,08217,7157,25830 Sep 1991,81418,48218,0587,88730 Jun 1992,36518,56618,4978,29131 Mar 1994,16517,77518,72410,26131 Dec 1894,12316,43119,41310,11830 Sep 1896,09117,01519,67210,21630 Jun 1897,59817,61519,9529,89531 Mar 1898,43019,04320,1748,15231 Dec 1799,40520,89319,8277,24330 Sep 1799,16021,43919,8546,46730 Jun 17100,21821,68419,9436,38731 Mar 17101,47922,01720,0206,45031 Dec 16103,26418,99220,2906,47630 Sep 16106,93620,10620,3026,54530 Jun 16108,32520,63920,1916,37431 Mar 16109,73021,14320,3025,88331 Dec 15108,16522,65120,0777,20130 Sep 15104,63018,96620,2207,20630 Jun 15100,05815,79220,6067,403質の高い収益: KKPC.Fは現在利益が出ていません。利益率の向上: KKPC.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: KKPC.Fは利益が出ておらず、過去 5 年間で損失は年間12.2%の割合で増加しています。成長の加速: KKPC.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: KKPC.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: KKPC.Fは現在利益が出ていないため、自己資本利益率 ( -2.63% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/11 20:07終値2026/01/13 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kaken Pharmaceutical Co., Ltd. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Kazuaki HashiguchiDaiwa Securities Co. Ltd.Junya YamazakiJefferies LLCToshiyuki IwataMizuho Securities Co., Ltd.6 その他のアナリストを表示
お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025
お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025
お知らせ • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
お知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
お知らせ • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.
お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025
お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • May 12+ 3 more updatesKaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.
お知らせ • Apr 11Kaken Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecast for Fiscal Year Ended March 31, 2025Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025.
お知らせ • Mar 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the purchase agreement and stock purchase. Completion of the stock purchase is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the stock purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor and Leerink Partners LLC acted as Financial advisor to Aadi Bioscience, Inc. Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million on March 25, 2025.
お知らせ • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025
お知らせ • Feb 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 1,800,000 shares, representing 4.53% for ¥9,000 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock.
お知らせ • Dec 22Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. Completion of the Stock Purchase is subject to customary closing conditions, including the approval of the Purchase Agreement and the Stock Purchase by the holders of a majority of the outstanding shares of Aadi’s capital stock entitled to vote to approve the Purchase Agreement and Stock Purchase, all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the Stock Purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor to
お知らせ • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
お知らせ • Sep 03Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024
お知らせ • Jun 26Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024
お知らせ • May 16Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.
お知らせ • Mar 03Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q4, 2024 results on May 09, 2024
お知らせ • Dec 08Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 06, 2024
お知らせ • Nov 15+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥176.92.
お知らせ • Sep 19Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)
お知らせ • Aug 30Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 08, 2023
お知らせ • Aug 18+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided dividend forecast for second quarter of 2024 and fiscal year ending March 31, 2024. For the quarter, the company expects to pay a dividend of ¥75 against ¥75 paid last year.For the year, the company expects to pay a dividend of ¥75 against ¥75 paid last year.
お知らせ • May 28Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023
お知らせ • May 12Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.
お知らせ • Dec 28Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 03, 2023